This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

19 Oct 2010

Galapagos achieves milestones in two stategic alliances

Belgian biotechnology fi10562m Galapagos has achieved milestones totalling €2.5m f10562om its alliances with Janssen Pha10562maceutica and GlaxoSmithKline (GSK).

Belgian biotechnology firm Galapagos has achieved milestones totalling €2.5m from its alliances with Janssen Pharmaceutica and GlaxoSmithKline (GSK).

Janssen Pharmaceutica has paid Galapagos €1.5m in its rheumatoid arthritis agreement, taking the total earned by Galapagos to date from Janssen to more than €24m.

In Galapagos'' alliance with GSK in the area of infectious diseases, the firm has received a €1m milestone payment. Since this alliance was formed in 2007, Galapagos has received a total of €6m from GSK.

‘Galapagos continues to make progress across its strategic alliances, showing that our alliance model delivers strong growth in r&d revenues,’ said Onno van de Stolpe, ceo of Galapagos.

In a separate announcement, Galapagos’ BioFocus service division has expanded its collaboration with Chiesi Farmaceutici, a privately held Italian pharmaceutical company. The total value of the collaboration has now reached €2.5m.

BioFocus and Ch

Related News